119 related articles for article (PubMed ID: 14621840)
1. The risk of infection following OKT3 and antilymphocyte globulin treatment for renal transplant rejection: results of a single center prospectively randomized trial.
Hesse UJ; Wienand P; Baldamus C; Pollok M; Pichlmaier H
Transpl Int; 1992; 5 Suppl 1():S440-3. PubMed ID: 14621840
[TBL] [Abstract][Full Text] [Related]
2. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
Hanto DW; Jendrisak MD; So SK; McCullough CS; Rush TM; Michalski SM; Phelan D; Mohanakumar T
Transplantation; 1994 Feb; 57(3):377-84. PubMed ID: 8108873
[TBL] [Abstract][Full Text] [Related]
3. Antilymphocyte globulins versus OKT3 as prophylactic treatment in highly sensitized renal transplant recipients.
Vela C; Cristol JP; Chong G; Okamba A; Lorho R; Mion C; Mourad G
Transpl Int; 1994; 7 Suppl 1():S259-62. PubMed ID: 11271219
[TBL] [Abstract][Full Text] [Related]
4. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study.
Grino JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Mestre M; Torras J; Alsina J
Am J Kidney Dis; 1992 Dec; 20(6):603-10. PubMed ID: 1462990
[TBL] [Abstract][Full Text] [Related]
5. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
Clark G; Walsh G; Deshpande P; Koffman G
Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
[TBL] [Abstract][Full Text] [Related]
6. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
Kitabayashi K; Munn SR; Sterioff S
Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
[No Abstract] [Full Text] [Related]
7. Antilymphocyte globulin with a small dose of cyclosporine A and prednisone as the induction of immunosuppression in renal allograft recipients.
Boratyńska M; Szepietowski T; Szewczyk Z; Szydłowski Z
Arch Immunol Ther Exp (Warsz); 1992; 40(2):163-8. PubMed ID: 1299176
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular effects of ATG and OKT3 in renal allograft recipients.
Spieker C; Barenbrock M; Buchholz B; Heidenreich S; Zidek W
Transplant Proc; 1992 Dec; 24(6):2594-5. PubMed ID: 1465876
[No Abstract] [Full Text] [Related]
9. Induction immunosuppression in kidney transplant recipients older than 60 years of age : safety and efficacy of ATGAM, OKT3 and Simulect.
Heifets M; Saeed MI; Parikh MH; Sierka D; Kumar MS
Drugs Aging; 2004; 21(11):747-56. PubMed ID: 15323580
[TBL] [Abstract][Full Text] [Related]
10. A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients.
Stratta RJ; Taylor RJ; Weide LG; Sindhi R; Sudan D; Castaldo P; Cushing KA; Frisbie K; Radio SJ
Transplant Proc; 1996 Apr; 28(2):917-8. PubMed ID: 8623461
[No Abstract] [Full Text] [Related]
11. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients.
Mariat C; Alamartine E; Diab N; de Filippis JP; Laurent B; Berthoux F
Transpl Int; 1998; 11(3):231-6. PubMed ID: 9638854
[TBL] [Abstract][Full Text] [Related]
12. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial.
Waid TH; Lucas BA; Thompson JS; McKeown JW; Brown S; Kryscio R; Skeeters LJ
Transplantation; 1997 Jul; 64(2):274-81. PubMed ID: 9256187
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomized study comparing poly-ATG to mono-OKT3 clonal antibodies for the first rejection therapy after kidney transplantation: long-term results.
Baldi A; Malaise J; Mourad M; Squifflet JP
Transplant Proc; 2000 Mar; 32(2):429-31. PubMed ID: 10715467
[No Abstract] [Full Text] [Related]
14. Diagnosis of viral infections under therapy with OKT3 and antithymocyte globulin.
Müller T; Sprenger H; Keuchel M; Neumann C; Ebel H; Gemsa D; Lange H
Transplant Proc; 1992 Dec; 24(6):2636-8. PubMed ID: 1334590
[No Abstract] [Full Text] [Related]
15. Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis.
Bailey TC; Powderly WG; Storch GA; Miller SB; Dunkel JD; Woodward RS; Spitznagel E; Hanto DW; Dunagan WC
Am J Kidney Dis; 1993 Feb; 21(2):196-201. PubMed ID: 8381577
[TBL] [Abstract][Full Text] [Related]
16. OKT3 salvage therapy in a quadruple immunosuppressive protocol in cadaveric renal transplantation.
D'Alessandro AM; Pirsch JD; Stratta RJ; Sollinger HW; Kalayoglu M; Maki DG; Belzer FO
Transplantation; 1989 Feb; 47(2):297-300. PubMed ID: 2493176
[TBL] [Abstract][Full Text] [Related]
17. Antibody therapy in steroid-resistant rejection.
Waiser J; Budde K; Schreiber M; Böhler T; Löbermann LA; Neumayer HH
Transplant Proc; 1998 Aug; 30(5):1778-9. PubMed ID: 9723279
[No Abstract] [Full Text] [Related]
18. Evaluation of OKT3 monoclonal antibody and anti-thymocyte globulin in the treatment of steroid-resistant acute allograft rejection in pediatric renal transplants.
Mochon M; Kaiser B; Palmer JA; Polinsky M; Flynn JT; Caputo GC; Baluarte HJ
Pediatr Nephrol; 1993 Jun; 7(3):259-62. PubMed ID: 8518094
[TBL] [Abstract][Full Text] [Related]
19. ALG versus OKT3 for treatment of steroid-resistant rejection in renal transplantation: ten-year follow-up results of a randomized trial.
Stippel DL; Arns W; Pollok M; Beckurts KT; Hesse UJ; Hölscher AH
Transplant Proc; 2002 Sep; 34(6):2201-2. PubMed ID: 12270362
[No Abstract] [Full Text] [Related]
20. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation.
Oh CS; Stratta RJ; Fox BC; Sollinger HW; Belzer FO; Maki DG
Transplantation; 1988 Jan; 45(1):68-73. PubMed ID: 3276066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
